Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Right Ventricular Function After Successful Reopening of Right Coronary Versus Left Circumflex Chronic Total Occlusions

15. November 2026 aktualisiert von: Amr Abdelbadee Abdelhameed Othman, Assiut University

Changes in Right Ventricular Function Following Successful Right Coronary Versus Left Circumflex Chronic Total Occlusion Revascularization

This study will compare changes in the function of the right side of the heart after successful treatment of a long-standing complete blockage in either the right coronary artery or the left circumflex coronary artery. Patients will receive catheter-based treatment because their clinical team has independently decided that it is appropriate; the study will not assign their artery or treatment technique.

The planned comparison includes 160 patients with successful treatment, with 80 in each artery group. Heart ultrasound will be performed within 14 days before the procedure and again six months afterward. A telephone follow-up will take place at three months. Conventional ultrasound measurements and speckle tracking, which measures deformation of the heart muscle, will be used to assess right ventricular function. The main comparison is the change in right ventricular free-wall longitudinal strain between the two groups.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Design and setting:

Prospective, single-centre observational cohort at Assiut University Heart Hospital, with consecutive recruitment within two prespecified vessel strata. Elective percutaneous coronary intervention (PCI) is selected independently of research participation. The operator determines the clinical PCI technique. No research treatment assignment, stress test, additional catheterization, experimental drug, biomarker assay or SAQ-7 questionnaire is required.

Cohort formation:

Baseline written consent and research echocardiography precede PCI. The main comparison comprises technically successful index procedures: residual stenosis less than 30% with final TIMI 3 flow. One index attempt per patient defines cohort entry. Unsuccessful procedures are recorded descriptively in the screening log and do not contribute to the primary successful-procedure comparison. Procedural complications do not retrospectively redefine technical success. The planned main cohort is 80 RCA and 80 LCX patients; this is distinct from the number of patients screened or consented before PCI.

Recruitment schedule:

Anticipated recruitment is from 1 January 2027 through 30 June 2028. Each participant is followed for six months after index PCI, with the specified visit window. Recruitment end is distinct from final outcome collection.

Assessments:

Baseline clinical and resting echo assessment occurs within 14 days before PCI; repeat baseline if an intervening acute event occurs. Angiographic anatomy, procedure strategy, result, complications and discharge treatment are recorded at the index admission. Three-month telephone contact, with a 14-day window, records vital status, symptoms, admissions and medication changes and reminds participants of the six-month visit. Six-month resting echo and clinical reassessment allow a 30-day window. Late assessments are retained for sensitivity analysis.

Imaging:

Conventional two-dimensional echocardiography and RV speckle tracking are performed using a Philips system with AutoStrain RV, after verification of installed software, native RVFWSL/RV4CSL outputs and image export. Manufacturer, model and software version are documented. An RV-focused apical four-chamber view is acquired, with at least three stable ECG-linked cycles. Patient-level outputs are averaged across three acceptable cycles. Native global free-wall strain is the primary measure; four-chamber strain includes the septum. Signed source values are preserved. Images with persistent tracking failure are not replaced by another endpoint. Conventional measurements include FAC, TAPSE, tissue-Doppler S-prime and RV basal diameter. LVEF, LV volumes, valve regurgitation, E/e-prime and estimated pulmonary artery systolic pressure provide clinical context. PASP is recorded only when technically measurable.

Anatomical characterization:

Coronary dominance, CTO location relative to major branches, previous target-territory infarction, collateral supply, residual coronary disease and J-CTO score are recorded. All dominance patterns are eligible. The LCX cohort is a disease comparator, not a healthy control.

Sample-size rationale:

The target of 160 successful cases uses assumed planning inputs: a 2-percentage-point between-group difference in individual strain magnitude change, a common change SD of 4 points, two-sided alpha 0.05 and 80% power. A noncentral-t calculation requires 64 complete patients per group, increased to 80 per group for 20% incomplete paired assessment. These assumptions are not direct RCA-versus-LCX effect estimates or established minimal clinically important differences. At an assumed 85% success rate, approximately 95 eligible attempts per vessel stratum may be needed; this is a planning estimate rather than observed local recruitment data.

Analysis:

The primary endpoint is compared using a two-sided Welch t test with a 95% confidence interval. Supportive ANCOVA models six-month strain magnitude with vessel group, baseline strain magnitude, baseline LVEF, age, prior myocardial infarction and coronary dominance. The primary complete-pair estimand concerns survivors with successful index PCI and interpretable baseline and follow-up imaging. Deaths, failed procedures, withdrawals and tracking failures are reported separately; post-death strain is not imputed. Missing survivor outcomes are addressed by multiple imputation when feasible and sensitivity analyses. Signed-strain analysis, patient-level bootstrap intervals and analysis excluding major interval events are prespecified sensitivity checks. Formal secondary testing of RV4CSL, FAC, TAPSE and S-prime uses Holm correction. Segmental strain and symptom analyses are exploratory. Clinical events are descriptive; the study is not powered for mortality or major cardiovascular events and does not establish a causal effect of PCI.

Quality and ethics:

A separate technical run-in of 10-15 cases checks acquisition and analysis feasibility. Twenty-five paired examinations are randomly selected for interobserver and intraobserver repeat analysis; readers are blinded to group and visit order where feasible. Written consent and required institutional and ethics approvals precede research procedures. Coded records and image files are stored securely with the identity key separately. Clinical care remains independent of participation.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

160

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Clinically stable adults attending Assiut University Heart Hospital with one native RCA or LCX chronic total occlusion and an independently established clinical indication for elective PCI. Consecutive eligible patients are assessed within each vessel stratum. The main comparison targets 80 technically successful index procedures in each group. Consent and baseline research imaging precede PCI; unsuccessful index procedures are recorded descriptively outside the main comparative cohort.

Beschreibung

Inclusion Criteria:

  • Age 18 years or older.
  • Clinically stable, with one native right coronary or left circumflex coronary artery chronic total occlusion, defined by TIMI 0 flow and documented or estimated duration of at least three months.
  • Independently selected for clinically indicated elective PCI.
  • Sinus rhythm and interpretable baseline RV-focused echocardiographic images.
  • Written informed consent before research procedures.
  • For inclusion in the main comparison: technically successful index CTO PCI, defined as residual stenosis less than 30% with final TIMI 3 flow.

Exclusion Criteria:

  • Acute coronary syndrome or myocardial infarction within 30 days.
  • Decompensated heart failure.
  • A second untreated chronic total occlusion.
  • Previous coronary artery bypass graft surgery.
  • Significant congenital heart disease.
  • Moderate or severe valvular heart disease.
  • Severe nonischemic pulmonary disease or pulmonary hypertension dominating RV dysfunction.
  • Persistent atrial fibrillation or paced rhythm preventing comparable analysis.
  • Inadequate baseline RV tracking.
  • Planned non-target revascularization during follow-up; clinically required other-vessel treatment should be completed before baseline when stable.

No arbitrary LVEF threshold is imposed. All coronary dominance patterns are eligible. Interval clinical deterioration, target-vessel failure, medication changes or clinically required subsequent revascularization do not retrospectively exclude an enrolled patient; they are recorded and follow-up is retained whenever possible.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Successful RCA CTO PCI

Adults with one native right coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

Elective PCI of a right coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.

Successful LCX CTO PCI

Adults with one native left circumflex coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.

Elective PCI of a left circumflex coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in right ventricular free-wall longitudinal strain magnitude
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Individual change is the absolute magnitude of six-month RV free-wall longitudinal strain minus its baseline absolute magnitude, measured in percentage points. Native Philips RVFWSL output is used and signed source values are retained. A positive magnitude change denotes greater systolic shortening. The primary comparison is the difference in mean individual change between the RCA and LCX cohorts. For illustration only, a change from -20% to -23% equals +3 percentage points in magnitude; this is not an observed result or the assumed between-group effect.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in right ventricular four-chamber longitudinal strain magnitude
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Change in native RV4CSL magnitude, including free wall and septum, from baseline to six months, in percentage points. Positive change denotes greater shortening magnitude; signed source values are preserved.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular fractional area change
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline RV fractional area change (FAC), in percentage points. FAC is 100 times (end-diastolic area minus end-systolic area) divided by end-diastolic area in an RV-focused view.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular plane systolic excursion
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline TAPSE, in millimetres, measured by aligned M-mode at the lateral tricuspid annulus.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular systolic tissue-Doppler velocity
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline systolic S-prime velocity, in centimetres per second, measured by pulsed tissue Doppler at the lateral tricuspid annulus.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular basal diameter
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline RV basal diameter, in millimetres, measured in the RV-focused apical four-chamber view.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in Canadian Cardiovascular Society angina class
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Baseline and six-month CCS angina class and individual class transitions are recorded. Classes I through IV indicate progressively greater limitation by angina; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in New York Heart Association functional class
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Baseline and six-month NYHA functional class and individual class transitions are recorded. Classes I through IV indicate progressively greater functional limitation; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in basal right ventricular free-wall segmental longitudinal strain magnitude
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in basal RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in mid right ventricular free-wall segmental longitudinal strain magnitude
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in mid RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in apical right ventricular free-wall segmental longitudinal strain magnitude
Zeitfenster: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in apical RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienstuhl: Hatem A. Helmy, MD, Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

31. Januar 2029

Studienabschluss (Geschätzt)

31. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

15. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. November 2026

Zuerst gepostet (Tatsächlich)

19. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • AssiutU-CARD-AAAO-0002

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

The IPD might not be shared according to the local institutional policy.

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .